What is Spravato?
In March 2019, Spravato, also called esketamine, was authorized by the FDA. Esketamine, a novel form of ketamine, is a nasal spray medication available by prescription. Formerly used primarily in veterinary medicine or in military settings, this anesthetic can now be administered through the nose and offers rapid and efficient advantages.
Spravato, an antidepressant, is prescribed for adults with major depressive disorder (MDD) who have not shown improvement with at least two other antidepressant medications given at appropriate doses for a sufficient duration, and who also experience acute thoughts of suicide or behaviors. This medication is also used to treat individuals with treatment-resistant depression (TRD).
The studies suggest that the efficacy of Spravato can range from 40-60% depending on the length of treatment. Randomized trials have shown that Spravato can quickly relieve treatment-resistant depression (TRD), but the rate of its effect may vary according to research.
The effectiveness of Spravato was evaluated through a single longer-term trial to assess its long-term effects and three four-week trials to evaluate its short-term effects. Patients in the short-term experiments were randomly given either Spravato or a placebo nasal spray. All patients started a new oral antidepressant simultaneously and continued taking it throughout the trials due to the severity of treatment-resistant depression (TRD) and the need for therapy.
However, two other short-term trials failed to pass the required statistical tests to demonstrate the effectiveness of Spravato, and within two days, some apparent effects on the severity of the short-term studies were statistically significant.
Patients who continued to receive Spravato alongside an oral antidepressant had significantly longer maintenance-of-effect in the longer-term trial, compared to patients with relapsing depressive symptoms who received a placebo nasal spray.
Risks & Side Effects of Spravato
The most frequent adverse reactions observed in clinical trials among patients treated with Spravato were:
In patients with poorly managed or uncontrolled hypertension, pre-existing vascular diseases or aneurysms may be more susceptible to complications. The reason for not approving Spravato for use in children is also due to the elevated risk of suicidal behaviors and thoughts in both young adults and children. Esketamine comes with boxed warnings about the potential danger of misuse and abuse, as well as the risk of dissociation and drowsiness.
The use of Spravato may potentially impair motor skills, response time, reasoning, judgment, and attention. Therefore, patients are advised not to drive or operate machinery until the day after receiving the drug. Pregnant women or those planning to conceive should exercise caution, as Spravato has the potential to harm a developing fetus. Additionally, women should refrain from breastfeeding while undergoing treatment.
Please remember that the oral antidepressant, rather than Spravato, may potentially result in certain side effects. If the adverse reactions continue, bother you, or worsen, it is advisable to consult your doctor. These side effects may last from a few days to several weeks.
Spravato, which can only be administered in a licensed healthcare setting with trained medical professionals who are authorized to prescribe and distribute it, is not available at your local pharmacy due to the Risk Evaluation and Mitigation Strategy (REMS) program. This program requires healthcare facilities that offer Spravato to be certified.
To mitigate the risks associated with administering specific medicines that may have serious side effects, the Food and Drug Administration (FDA) initiated the REMS program. REMS programs aid in the management of medications. Moreover, healthcare professionals receive guidance on closely overseeing and prescribing these medicines. This enables Spravato physicians to assess whether the benefits of the drug outweigh the risks.
Does Blue Cross Blue Shield Cover Spravato (Esketamine) Treatments?
The requirements for approval of the Federal Employee Program’s Blue Cross Blue Shield vary depending on the state and insurance provider. Before insuring this nasal spray, esketamine, certain criteria must be met. BCBS coverage for this drug, esketamine nasal spray, depends on your specific health plan and diagnosis.
Jump to Section
How to Verify BCBS Coverage for Spravato
The most effective way to determine if Tennessee’s BCBS coverage includes Spravato is by filling out our online insurance verification form, which is confidential and free. Spravato treatment clinics, including Care Athena, are in-network with most major insurance plans.
Allow our highly skilled care coordinators to handle the hassles of contacting your insurance company for more information about Spravato benefits. They will thoroughly explain your options and review your insurance coverage to ensure that all confidential information is kept secure and shared only with authorized individuals.
How Much Does Spravato Cost Without Insurance?
In Tennessee, the real expense of Spravato therapy might not mirror what you will be charged. They could vary depending on the location and other factors. The subsequent figures represent the typical expenses for the medication in the absence of BCBS Spravato coverage.
Following each month, the costs can vary from approximately $1,416 to $4,248. In the second month, the expenses range from $2,832 to $4,248, and during the initial month of treatment, the costs can be between $5,664 and $8,142, depending on the dosing frequency, whether it is weekly or bi-weekly. Eventually, the overall expenses for Spravato will be lower, but at the start of the treatment, it is expected to be higher.
Sources
If you suspect that you or someone you love suffers from mental health disorders, contact Athena Care today.
Control take and better feel to step first this take. Need you help the get you will associates friendly our of one.